These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 8531099

  • 1. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
    Marie C, Mossiat C, Lecomte JM, Schwartz JC, Bralet J.
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1324-31. PubMed ID: 8531099
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Acute natriuretic effect of fasidotrilat, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in rats with heart failure.
    Marie C, Mossiat C, Lecomte JM, Bralet J.
    Pharmacology; 1998 Jun; 56(6):291-6. PubMed ID: 9654215
    [Abstract] [Full Text] [Related]

  • 4. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
    Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL.
    J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
    [Abstract] [Full Text] [Related]

  • 5. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK, Johnston CI, Burrell LM.
    J Hypertens; 2000 Jun; 18(6):749-55. PubMed ID: 10872560
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat.
    Lapointe N, Blais C, Adam A, Parker T, Sirois MG, Gosselin H, Clément R, Rouleau JL.
    J Am Coll Cardiol; 2002 May 15; 39(10):1692-8. PubMed ID: 12020499
    [Abstract] [Full Text] [Related]

  • 7. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR.
    J Pharmacol Exp Ther; 1996 Feb 15; 276(2):708-13. PubMed ID: 8632340
    [Abstract] [Full Text] [Related]

  • 8. [Activation of the cardiac angiotensin-converting enzyme after myocardial infarction and its role in ventricular remodeling].
    Mill JG, Milanez Mda C, Busatto VC, de Moraes AC, Gomes Mda G.
    Arq Bras Cardiol; 1997 Aug 15; 69(2):101-10. PubMed ID: 9567332
    [Abstract] [Full Text] [Related]

  • 9. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure.
    Trippodo NC, Robl JA, Asaad MM, Bird JE, Panchal BC, Schaeffer TR, Fox M, Giancarli MR, Cheung HS.
    J Pharmacol Exp Ther; 1995 Nov 15; 275(2):745-52. PubMed ID: 7473162
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog].
    Richard V, Lecomte JM, Thuillez C.
    Arch Mal Coeur Vaiss; 1993 Aug 15; 86(8):1275-9. PubMed ID: 8129543
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
    Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X.
    Clin Exp Pharmacol Physiol; 1999 Nov 15; 26(11):903-8. PubMed ID: 10561812
    [Abstract] [Full Text] [Related]

  • 15. Effects of captopril and omapatrilat on early post-myocardial infarction survival and cardiac hemodynamics in rats: interaction with cardiac cytokine expression.
    Blais C, Lapointe N, Rouleau JL, Clément R, Bachvarov DR, Adam A.
    Can J Physiol Pharmacol; 2002 Jan 15; 80(1):48-58. PubMed ID: 11911226
    [Abstract] [Full Text] [Related]

  • 16. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
    Duncan AM, James GM, Anastasopoulos F, Kladis A, Briscoe TA, Campbell DJ.
    J Pharmacol Exp Ther; 1999 Apr 15; 289(1):295-303. PubMed ID: 10087017
    [Abstract] [Full Text] [Related]

  • 17. Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.
    Wegner M, Hirth-Dietrich C, Knorr A, Dressel J, Ganten D, Stasch JP.
    Hypertens Res; 1996 Sep 15; 19(3):151-9. PubMed ID: 8891743
    [Abstract] [Full Text] [Related]

  • 18. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
    Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S.
    J Pharmacol Exp Ther; 2003 Apr 15; 305(1):97-105. PubMed ID: 12649357
    [Abstract] [Full Text] [Related]

  • 19. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
    Trippodo NC, Gabel RA, Harvey CM, Asaad MM, Rogers WL.
    J Cardiovasc Pharmacol; 1991 Sep 15; 18(3):308-16. PubMed ID: 1720829
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
    Gonzalez W, Beslot F, Laboulandine I, Fournié-Zaluski MC, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1996 Aug 15; 278(2):573-81. PubMed ID: 8768706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.